Almac Clinical Technologies announced today that its Testing Department has completed the ISTQB Software certification.
Almac Testers Receive ISTQB Software Testing Certification
2 July 2008 Yardley, Pennsylvania. Almac Clinical Technologies announced today that its Testing Department has completed the ISTQB Software certification. ISTQB (International Software Testing Qualification Board, Inc.) is the most widely recognized Software Tester certification organization in the world. Almac is one of the first clinical technology organizations to receive this certification. This training assures sponsors that Almac is continuously committed to providing the highest quality technical solutions for its clients.
The testers of Almac Clinical Technologies have been awarded the designation of Certified Tester, Foundation Level (CTFL). The Foundation Level exam tests for software testing knowledge and proficiency, as well the certificate holder's level of familiarity with software testing concepts and industry standard terminology. The Almac Clinical Technologies Testing Department is now part of an elite group of software testers throughout the world that currently hold ISTQB compliant certificates.
Karen Borda, Vice President of Production IT, says “Successfully completing the ISTQB certification for software testing sends another signal to our clients that Almac Clinical Technologies is committed to operational excellence, high-quality service performance, and providing compliant solutions in a timely manner. At Almac we take pride in working consultatively with our clients to understand their needs, gather their trial requirements, and provide innovative solutions for each trial. The ISTQB certification gives us a technological edge over our competitors and reinforces our industry-leading reputation for high quality products supported by our commitment to staff excellence. We aim to be a couple of notches above our competition and this certification supports that goal.”
Jim Murphy, President of Almac Clinical Technologies adds, “At Almac we realize that the power of technology is enhanced through superior project management, customer service and highly-trained employees. Given the technological challenges faced by our clients in the biopharmaceutical industry, Almac Clinical Technologies provides rigorous training for its employees, the ISTQB being just one of many programs we have completed to build our expertise in technology and project management.”
About Almac
Almac Clinical Technologies is a division of the Almac Group that specializes in interactive technology and service solutions to increase the quality and efficiency of the clinical trial process. Our solutions include Interactive Voice and Web Response Systems (IXRS™) for patient randomization; tracking and clinical supply management; iTrial EDC for electronic case report form data collection; electronic patient reported outcome data collection; and web drug reconciliation.
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 2,000 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.